Evidence map›Paper›PMID 37918510›Full record

ReviewClinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases2024

Tuberculosis prevention: current strategies and future directions.

Anca Vasiliu, Leonardo Martinez, Rishi K Gupta, Yohhei Hamada, Tara Ness, Alexander Kay, Maryline Bonnet, Martina Sester, Stefan H E Kaufmann, Christoph Lange and 1 more

Open access · greenAbstract readReview
In one paragraph

Review in Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 64 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
64citing papers in PubMed, 3 pooled it
16.7field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

64 citing papers in PubMed, 3 syntheses or guidelines pooled it, 86 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Review
  6. Article
  7. Article
  8. Article
  9. Monoclonal Antibodies Targeting Bacterial Infections: A Broad Review of the Field.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2026
    Review
  10. Article
  11. Article
  12. EliminateJournal of medical microbiology · 2026
    Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

4 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 7 institutions in 4 countries.

Anca VasiliuDepartment of Pediatrics, Baylor College of Medicine, Global TB Program, Houston, TX, USA. Electronic address: anca.vasiliu@bcm.edu.
Leonardo MartinezDepartment of Epidemiology, School of Public Health, Boston University, Boston, MA, USA.
Rishi K GuptaInstitute of Health Informatics, University College London, London, United Kingdom.
Yohhei HamadaInstitute for Global Health, University College London, London, United Kingdom.
Tara NessDepartment of Pediatrics, Baylor College of Medicine, Global TB Program, Houston, TX, USA.
Alexander KayDepartment of Pediatrics, Baylor College of Medicine, Global TB Program, Houston, TX, USA.
Maryline BonnetUniversity of Montpellier, TransVIHMI, IRD, INSERM, Montpellier, France.
Martina SesterDepartment of Transplant and Infection Immunology, Saarland University, Homburg, Germany.
Stefan H E KaufmannDepartment of Immunology, Max Planck Institute for Infection Biology, Berlin, Germany; Systems Immunology (Emeritus Group), Max Planck Institute for Multidisciplinary Sciences, Göttingen, Germany; Hagler Institute for Advanced Study, Texas A&M University, College Station, TX, USA.
Christoph LangeDepartment of Pediatrics, Baylor College of Medicine, Global TB Program, Houston, TX, USA; Division of Clinical Infectious Diseases, Research Center Borstel, Borstel, Germany; German Center for Infection Research (DZIF), Partner Site Hamburg-Lübeck-Borstel-Riems, Borstel, Germany; Respiratory Medicine and International Health, University of Lübeck, Lübeck, Germany.
Anna M MandalakasDepartment of Pediatrics, Baylor College of Medicine, Global TB Program, Houston, TX, USA; Division of Clinical Infectious Diseases, Research Center Borstel, Borstel, Germany; German Center for Infection Research (DZIF), Partner Site Hamburg-Lübeck-Borstel-Riems, Borstel, Germany.
Baylor College of Medicine · USUniversity College London · GBBoston University · USGerman Center for Infection Research · DEInserm · FRInstitute for Advanced Study · USSaarland University · DE

Funding

Quantifiable stool-based TB PCR to Improve Diagnostics and Treatment MonitoringR01AI137527 · NIAID · BAYLOR COLLEGE OF MEDICINE · PI MANDALAKAS, ANNA M · 2019 to 2022
$2.7M
Developing Clinical Prediction Tools to Define Strategies for Differentiated Service Delivery in Children and Adolescents Living with HIV in sub-Saharan Africa.K01TW011482 · FIC · BAYLOR COLLEGE OF MEDICINE · PI KAY, ALEXANDER WILLIAM · 2020 to 2024
$749k
FIC NIH HHS K01 TW011482NIAID NIH HHS R01 AI137527
6 · The paper itself

Abstract

backgroundAn estimated one fourth of the world's population is infected with Mycobacterium tuberculosis, and 5-10% of those infected develop tuberculosis in their lifetime. Preventing tuberculosis is one of the most underutilized but essential components of curtailing the tuberculosis epidemic. Moreover, current evidence illustrates that tuberculosis manifestations occur along a dynamic spectrum from infection to disease rather than a binary state as historically conceptualized. Elucidating determinants of transition between these states is crucial to decreasing the tuberculosis burden and reaching the END-TB Strategy goals as defined by the WHO. Vaccination, detection of infection, and provision of preventive treatment are key elements of tuberculosis prevention.

objectivesThis review provides a comprehensive summary of recent evidence and state-of-the-art updates on advancements to prevent tuberculosis in various settings and high-risk populations. SOURCES: We identified relevant studies in the literature and synthesized the findings to provide an overview of the current state of tuberculosis prevention strategies and latest research developments. CONTENT: We present the current knowledge and recommendations regarding tuberculosis prevention, with a focus on M. bovis Bacille-Calmette-Guérin vaccination and novel vaccine candidates, tests for latent infection with M. tuberculosis, regimens available for tuberculosis preventive treatment and recommendations in low- and high-burden settings. IMPLICATIONS: Effective tuberculosis prevention worldwide requires a multipronged approach that addresses social determinants, and improves access to tuberculosis detection and to new short tuberculosis preventive treatment regimens. Robust collaboration and innovative research are needed to reduce the global burden of tuberculosis and develop new detection tools, vaccines, and preventive treatments that serve all populations and ages.

Indexed as

Mycobacterium tuberculosisTuberculosisBCG VaccineGlobal HealthHumansTuberculosis VaccinesVaccinationBCG VaccineTuberculosis VaccinesBCGIGRALTBINovel vaccine candidatesPreventive treatmentTB spectrumTPTTSTTuberculosis control

Identifiers

PMID37918510
PMCPMC11524220
OpenAlexW4388080019

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.